Regulus Therapeutics to Attend Two Healthcare Investment Conferences

Regulus Therapeutics Inc., a biopharmaceutical company listed on Nasdaq under the ticker symbol RGLS, is dedicated to the discovery and development of pioneering medicines that target microRNAs. The company has recently announced its participation in two upcoming investor conferences.

Regulus will take part in the Wells Fargo Healthcare Conference, where a fireside chat is scheduled for Wednesday, September 4, 2024, at 2:15 p.m. ET. Additionally, the company will be present at the H.C. Wainwright 26th Annual Global Investment Conference, with another fireside chat planned for Monday, September 9, 2024, at 10:00 a.m. ET. Both events will be broadcast live, and the recordings of these presentations will be accessible in the "Events and Presentations" section of Regulus's investor relations webpage. These recordings will remain available for 90 days following their respective dates.

Regulus Therapeutics Inc., headquartered in San Diego, CA, focuses on creating innovative medicines that target microRNAs. The company utilizes its expertise in oligonucleotide drug discovery and development to build a robust pipeline. This pipeline is supported by a substantial intellectual property portfolio within the microRNA research field.

The company's strategic participation in these conferences highlights its commitment to engaging with the investment community and providing updates on its progress and future plans. Such interactions are vital for keeping current and potential investors informed about the company's endeavors and milestones.

Regulus's approach involves leveraging its oligonucleotide technology to tackle various medical challenges. This technology forms the backbone of the company's efforts to develop new therapeutic solutions. The company's robust intellectual property estate provides a strategic advantage in the competitive field of microRNA-targeted therapies.

Through these conferences, Regulus aims to showcase its latest developments and achievements to investors and other stakeholders. These events offer a platform for the company to discuss its ongoing projects, future outlook, and the impact of its innovative approaches on the medical and scientific communities.

The participation in the Wells Fargo Healthcare Conference and the H.C. Wainwright Global Investment Conference is part of Regulus's broader strategy to maintain transparency and open communication with its investors. By doing so, the company seeks to build and sustain investor confidence, while also attracting new investment opportunities to support its growth and development initiatives.

In summary, Regulus Therapeutics Inc. continues to advance its mission of developing groundbreaking microRNA-targeted therapies. The company's engagement in prominent investor conferences underscores its proactive approach to investor relations and commitment to transparency. Through these efforts, Regulus aims to keep the investment community well-informed about its progress, strategic direction, and potential for future success.